玛伐凯泰在射血分数正常及超常心力衰竭中的心肌肌球蛋白抑制:EMBARK-HFpEF 试验主要结果
EMBARK-HFpEF 是一项 2a 期、开放标签、单臂、多中心试验,纳入 30 例 LVEF≥60% 的症状性 HFpEF 患者,接受玛伐凯泰治疗 26 周。结果显示 NTproBNP、hsTnT 和 hsTnI 较基线显著降低,NYHA 心功能分级改善,LVEF 平均下降 3.2 个百分点,无 LVEF<30% 或死亡。
要点
- 玛伐凯泰治疗 26 周降低 NTproBNP、hsTnT 和 hsTnI,停药 8 周后生物标志物向基线回升。
- 41.7% 可评估患者 NYHA 心功能分级改善,舒张功能超声指标改善。
- LVEF 平均下降 3.2 个百分点,3 例因预设 LVEF 标准中断治疗,均恢复。
核心结论
- 在 LVEF≥60% 的 HFpEF 患者中,玛伐凯泰与心脏壁应力及损伤生物标志物改善相关,未观察到 LVEF 持续下降。
研究设计与样本
- 共纳入 30 例有症状 HFpEF 患者,NYHA II 或 III 级、LVEF≥60%、NTproBNP 升高且伴左心室肥厚,接受玛伐凯泰治疗 26 周。
- 玛伐凯泰起始 2.5 mg,第 14 周根据预设 LVEF 和 NTproBNP 标准可滴定至 5 mg。
主要发现
- 停药 8 周后心脏生物标志物向基线水平回升。
- 24 例末次治疗时可评估 NYHA 的患者中 10 例(41.7%)NYHA 分级改善,并观察到左室舒张功能超声指标改善。
关键数值与推荐
- 入选标准:有症状 HFpEF(NYHA II 或 III 级)、LVEF≥60%、NTproBNP 升高、左心室肥厚。
- 玛伐凯泰起始 2.5 mg,第 14 周根据预设 LVEF 和 NTproBNP 标准可滴定至 5 mg。
- 预设中断标准包括 LVEF<50% 或较基线相对下降>20%。
临床怎么用
- 对于 LVEF≥60% 的症状性 HFpEF 患者,玛伐凯泰可能改善心脏壁应力和损伤生物标志物及 NYHA 分级。
- 治疗期间需监测 LVEF,按预设标准(LVEF<50% 或相对下降>20%)及时中断治疗。
局限性
- 本研究为开放标签、单臂设计,样本量 30 例,无对照组。
- 研究期限 26 周,长期疗效和安全性未评估。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Patients with heart failure with preserved ejection fraction (HFpEF) who have left ventricular ejection fraction (LVEF) of 60% or greater have limited treatment options. OBJECTIVE: To examine the effects of cardiac myosin inhibition with mavacamten in patients with HFpEF with LVEF of 60% or greater. DESIGN, SETTING, AND PARTICIPANTS: The EMBARK-HFpEF trial was a phase 2a, open-label, single-arm, multicenter trial conducted from November 6, 2020, to February 26, 2024, at 20 sites in the US and Canada. Patients with symptomatic HFpEF (defined as a New York Heart Association [NYHA] functional class II or III), LVEF of 60% or greater, elevated N-terminal pro-B-type natriuretic peptide (NTproBNP), and left ventricular hypertrophy were eligible for inclusion. INTERVENTION: Mavacamten treatment for 26 weeks, starting at 2.5 mg and potentially titrated up to 5 mg at week 14 based on prespecified LVEF and NTproBNP criteria. MAIN OUTCOMES AND MEASURES: Primary efficacy end points (measured as the change from baseline to week 26) included NTproBNP and high-sensitivity troponin T (hsTnT); additional efficacy end points included changes in high-sensitivity troponin I (hsTnI), NYHA functional class, and echocardiographic parameters (resting and peak exercise). Safety end points included treatment-emergent adverse events and reductions in LVEF to less than 30%. RESULTS: A total of 30 patients were enrolled and treated with mavacamten. Median (IQR) patient age was 76 (70-80) years, and 16 patients (53.3%) were female. From baseline to week 26, mavacamten was associated with reductions in NTproBNP (mean reduction, -26%; 95% CI, -44% to -4%; P = .04), hsTnT (mean reduction, -13%; 95% CI, -23% to -3%; P = .02), and hsTnI (mean reduction, -20%; 95% CI, -32% to -6%; P = .01). Cardiac biomarker values returned toward baseline levels 8 weeks after drug discontinuation. NYHA class improved in 10 of 24 patients (41.7%) who had evaluable NYHA class data at the end of treatment, and improvements in echocardiographic markers of LV diastolic function were observed. Mean LVEF decreased by 3.2 absolute percentage points (95% CI, 1.1-5.4; P = .005) during treatment. Mavacamten was interrupted in 3 patients (10% of the study population; 95% CI, 2.1%-26.5%) due to protocol prespecified criteria of LVEF less than 50% (n = 2) or a more than 20% relative decrease from baseline (n = 1; nadir LVEF, 58%), with LVEF recovery observed in all 3 patients. There were no deaths or instances of LVEF less than 30%; 1 patient had worsening heart failure deemed unrelated to the study drug. CONCLUSIONS AND RELEVANCE: In an open-label trial in patients with HFpEF with LVEF of 60% or greater, mavacamten was associated with improvements in biomarkers of cardiac wall stress and injury, with no sustained reductions in LVEF observed. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT04766892.
引用
- Shah, Rigolli, Javidialsaadi, et al. Cardiac Myosin Inhibition in Heart Failure With Normal and Supranormal Ejection Fraction: Primary Results of the EMBARK-HFpEF Trial. JAMA Cardiol. 2025. PMID: 39347697. doi:10.1001/jamacardio.2024.3810
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。